Summary
IDEXX Laboratories, Inc. (IDXX) reported robust revenue growth for the fiscal year ending December 31, 2013, demonstrating resilience and continued expansion across its core business segments. The company's strategic focus on its Companion Animal Group (CAG) continues to yield strong results, driven by recurring revenue from consumables and services, complemented by the placement of new diagnostic instruments. The diversification into Water and Livestock, Poultry, and Dairy (LPD) segments also contributes to overall financial health, although performance in these areas shows varying trends. IDEXX's commitment to innovation and product development is evident through its ongoing research and development investments, aiming to further solidify its market leadership and drive future growth. Financially, the company exhibits a healthy balance sheet with growing cash reserves and effective management of operating expenses. IDEXX actively returned capital to shareholders through a significant share repurchase program and demonstrated its ability to access capital markets effectively, as evidenced by the issuance of senior notes. The company's operational efficiency and strategic execution position it for sustained performance in the dynamic veterinary and diagnostic markets.
Financial Highlights
52 data points| Revenue | $1.38B |
| Cost of Revenue | $620.94M |
| Gross Profit | $756.12M |
| R&D Expenses | $88.00M |
| Operating Income | $266.76M |
| Interest Expense | $5.39M |
| Net Income | $187.80M |
| EPS (Basic) | $1.77 |
| EPS (Diluted) | $1.74 |
| Shares Outstanding (Basic) | 106.32M |
| Shares Outstanding (Diluted) | 107.97M |
Key Highlights
- 1IDEXX Laboratories reported total revenue of $1.38 billion for the fiscal year ended December 31, 2013, representing a 6.5% increase year-over-year.
- 2The Companion Animal Group (CAG) remains the primary revenue driver, with diagnostics recurring revenue (consumables, services) showing a strong 8.7% increase, highlighting the success of its recurring revenue model.
- 3Instrument placements, particularly for newer analyzers like Catalyst Dx and ProCyte Dx, continue to grow, supporting future consumable sales.
- 4The company maintained healthy gross profit margins, with overall gross profit increasing by 8.1% to $756.1 million.
- 5Research and Development expenses increased to $88.0 million, reflecting a continued commitment to innovation and new product development.
- 6IDEXX actively repurchased shares, spending $367.8 million on buybacks in 2013, demonstrating a commitment to returning value to shareholders.
- 7The company ended the year with a strong cash position of $279.1 million and significant borrowing availability.